Nataraj Kalyanaraman leads the Drug Development organization in Hyderabad. Nataraj is focused on establishing holistic drug development capabilities in Hyderabad that support the BMS mission of helping patients prevail over serious disease. Key focus areas are expanding the global reach of drug development capabilities by driving operational delivery of clinical trial activities.

Prior to this, he held various leadership roles at BMS in Switzerland and the U.S., helping build global drug development strategies and capabilities, including scientific diligence and post-merger integration activities for notable acquisitions (Celgene and MyoKardia) and annual portfolio strategy and optimization efforts. He has also led global expansion strategies for BMS in countries such as China, Japan, and Switzerland.

Nataraj has two decades of experience across research and development strategy and operations in the biopharma, healthcare payers, and global health sectors. Prior to joining BMS in 2017, he was a strategy consultant at PwC’s pharma and life sciences practice, where he advised on R&D strategy across a diverse set of companies in the healthcare ecosystem, included biopharmas such as Pfizer, Lilly, Astellas, Takeda and AbbVie, healthcare payers and providers, as well as global health leaders such as the Bill and Melinda Gates Foundation and Global Health Innovative Technology Fund. He began his career as a medicinal chemist, working as a pharmacokinetics and drug metabolism scientist at Amgen.

Nataraj is based in Hyderabad and holds a B.S. in pharmacy from the University of Mumbai, an M.S. in medicinal chemistry from the University of Minnesota, and an MBA from the University of California, Los Angeles.